Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

The Lancet Gastroenterology & Hepatology in conversation with - A podcast by The Lancet Group

Categories:

Education

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedic...